| NEOPHARMED-GENTILI-S-P-A |
NEOPHARMED-GENTILI-S-P-A |
92%
|
the Company entered into a license agreement granting an Irish affiliate of Neopharmed Gentili S.p.A. exclusive rights to commercialize navenibart for hereditary angioedema in Europe |
| BIOCRYST-IRELAND |
BIOCRYST-IRELAND |
90%
|
The Company receives quarterly royalty payments from BioCryst Ireland equal to amounts owed under its Royalty Purchase Agreements with RPI and OMERS for the sale of ORLADEYO products in the Territory. |
| SPECIALTY-PHARMACY |
SPECIALTY-PHARMACY |
90%
|
Product revenue where the specialty pharmacy is considered the customer was approximately 93 % and 85 % of total product sales for the three months ended March 31, 2026 and 2025, respectively. |
| ANNORA-HETERO-LABS-LIMITED-HETERO-USA-INC |
ANNORA-HETERO-LABS-LIMITED-HETERO-USA-INC |
62%
|
ed awards would have been forfeited upon the employees’ termination with the Company at closing. As part of the transaction, the Company 25 Table of Contents approved modifications that (i) allowed p… |
| ANNORA-PHARMA-PRIVATE-LIMITED |
ANNORA-PHARMA-PRIVATE-LIMITED |
62%
|
ed awards would have been forfeited upon the employees’ termination with the Company at closing. As part of the transaction, the Company 25 Table of Contents approved modifications that (i) allowed p… |
| ASTRIA-THERAPEUTICS-INC |
ASTRIA-THERAPEUTICS-INC |
62%
|
. The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the “Royalty Sales”. Under the Royalty Purchase Agreements, the Company has agreed to specified af… |
| ATHYRIUM-OPPORTUNITIES-III-CO |
ATHYRIUM-OPPORTUNITIES-III-CO |
62%
|
. The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the “Royalty Sales”. Under the Royalty Purchase Agreements, the Company has agreed to specified af… |
| BIOCRYST-IRELAND-LIMITED |
BIOCRYST-IRELAND-LIMITED |
62%
|
ended March 31, 2026: Balance at December 31, 2025 $ — Workforce reduction expense recorded during the three months ended March 31, 2026 11,927 Amounts paid during the three months ended March 31, 20… |
| BIOPHARMA-CREDIT-PLC |
BIOPHARMA-CREDIT-PLC |
62%
|
. The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the “Royalty Sales”. Under the Royalty Purchase Agreements, the Company has agreed to specified af… |
| BPCR-LIMITED |
BPCR-LIMITED |
62%
|
. The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the “Royalty Sales”. Under the Royalty Purchase Agreements, the Company has agreed to specified af… |
| CAMBER-PHARMACEUTICALS-INC |
CAMBER-PHARMACEUTICALS-INC |
62%
|
ed awards would have been forfeited upon the employees’ termination with the Company at closing. As part of the transaction, the Company 25 Table of Contents approved modifications that (i) allowed p… |
| COMPANY-AXEL-MERGER-SUB-INC |
COMPANY-AXEL-MERGER-SUB-INC |
62%
|
uct, commercial revenue and product candidates. Further, the Company’s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perf… |
| OCM-IP-HEALTHCARE-HOLDINGS-LIMITED |
OCM-IP-HEALTHCARE-HOLDINGS-LIMITED |
62%
|
ly resulting from interest rate changes. The Company does not have an intent to sell these investments, and it is more likely than not that the investments will be held until recovery of their amorti… |
| OTHER-RELATIONSHIPS-NAVENIBART-KAKEN-PHARMACEUTI |
OTHER-RELATIONSHIPS-NAVENIBART-KAKEN-PHARMACEUTI |
62%
|
ed awards would have been forfeited upon the employees’ termination with the Company at closing. As part of the transaction, the Company 25 Table of Contents approved modifications that (i) allowed p… |
